Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 10/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.35 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5106293 | 0.83 | SLC7A5 (0.39) | DPP4 | |
| SCHEMBL5115637 | 0.79 | SCN9A (0.38) | SCN9ASCN5A | |
| SCHEMBL243272 | 0.71 | TRPA1 (0.47) | — | |
| SCHEMBL14022204 | 0.70 | SCN9A (0.59) | SCN9A | |
| SCHEMBL1142200 | 0.70 | SCN9A (0.59) | SCN9A | |
| SCHEMBL5109997 | 0.69 | SLC7A5 (0.40) | DPP4 | |
| SCHEMBL5109170 | 0.69 | SLC7A5 (0.43) | DPP4 | |
| SCHEMBL1142219 | 0.68 | SCN9A (0.46) | SCN9A | |
| SCHEMBL5105417 | 0.68 | CCNA2 (0.38) | SCN9ASCN5APARP10XDH | |
| SCHEMBL1142586 | 0.67 | SCN9A (0.51) | SCN9ADPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329764-B2 | Substitute benzothiophene compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| EP-1651629-A1 | SUBSTITUTED BENZOTHIOPHENE COMPOUNDS AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20050038104-A1 | Substitute benzothiophene compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-17 | — | — | US | disclosed |
| WO-2005012283-A1 | SUBSTITUTED BENZOTHIOPHENE COMPOUNDS AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038104-A1 | Substitute benzothiophene compounds | TST, SULT1E1, LTC4S | SCN9A 4314/4885SCN5A 4039/4885PARP10 1480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.